Web Release
Date: May 20,
Characterization of Nonmutagenic Cr(III)-DNA Interactions
Department of Chemistry, Northern Arizona University, P.O. Box 5698, Flagstaff, Arizona 86011-5698
Received January 10, 2003
Abstract:
Exposure of cells or animals to carcinogenic chromium(VI) (Cr(VI)) produces
Cr(III)-DNA adducts. The relevance of these lesions to Cr(VI)-induced tumors is
unclear. Various Cr(III) complexes have been used to model the products
resulting from Cr(VI) metabolism in order to gain mechanistic insights. The
purpose of this study was to characterize interactions of Cr(III) complexes with
DNA in order to evaluate their use as models for these purposes. The reactivity
of DNA with chromic chloride hexahydrate (CrCl3) and sodium bis(L-cysteinato)chromium(III) dihydrate
(Cr(cys)2-) was compared to that with
cis-diamminedichloroplatinum(II) (cis-platin). Both Cr(III) and
Pt(II) cause unwinding of supercoiled DNA that can be visualized as a mobility
shift by gel electrophoresis. Chromic chloride was much less distorting than
cis-platin, unwinding DNA by only 1-2
,
and Cr(cys)2- interacted with DNA only weakly. Consistent
with in vitro studies, CrCl3 produced Cr-DNA adducts in CHO AA8 cells
at levels equivalent to those obtained with Cr(VI), whereas
Cr(cys)2- did not produce significant adducts. Lesions
produced by CrCl3 were not mutagenic in the
hypoxanthine-Gua-phosphoribosyl-transferase assay. These data are consistent
with CrCl3 producing a nondistorting lesion, perhaps by association
with the phosphate backbone. There are two possible interpretations of these
results: Either the Cr(III) products formed by Cr(VI) metabolism are not modeled
by CrCl3 and Cr(cys)2- complexes, or Cr(III) is
not an active species for Cr(VI)-induced DNA damage. This study provides the
first structural evidence for Cr(III)-DNA adducts. A molecular understanding of
Cr(III)-DNA interactions will be necessary before we can determine their
relevance in Cr(VI)-induced cancers.